RT Journal Article
SR Electronic
T1 Relationship between tumor mutational burden (TMB) and SUVmax in 18F-FDG PET in cancer patients
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1237
OP 1237
VO 61
IS supplement 1
A1 Haghighat Jahromi, Amin
A1 Zabel, Matthew
A1 Barkauskas, Donald
A1 Nikanjam, Mina
A1 Frampton, Garret
A1 Goodman, Aaron
A1 Hoh, Carl
A1 Kurzrock, Razelle
YR 2020
UL http://jnm.snmjournals.org/content/61/supplement_1/1237.abstract
AB 1237Background: Radiogenomics is an evolving field that links radiologic and genomic data. 18F-FDG PET/CT is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters. Methods: In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that had no systemic treatment prior to imaging/biopsy, and also had 18F-FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation. Results: We found a linear correlation between TMB and SUVmax (p<0.001). In the multivariate analysis, only TMB correlated with SUVmax whereas age, gender and tumor histology did not. TMB independently associated with SUVmax. Conclusion: This correlation links the SUVmax in readily available, routinely used, and non-invasive 18F-FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been suggested to predict better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy. <!--EndFragment-->